Ocugen (OCGN) Depreciation & Amortization (CF) (2014 - 2026)
Ocugen (OCGN) posted Depreciation & Amortization (CF) of $590000.0 for Q1 2026, up 248.61% on a QoQ basis from -$397000.0 in Q4 2025, and down 0.84% year-over-year from $595000.0 in Q1 2025.
Ocugen (OCGN) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
Ocugen's Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $590000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 0.84% year-over-year to $590000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $2.4 million, up 21.39% from the prior year.
- Depreciation & Amortization (CF) was $590000.0 for Q1 2026 at Ocugen, up from -$397000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.2 million in Q2 2025 and bottomed at -$397000.0 in Q4 2025.
- A 5-year average of $360647.1 and a median of $179000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) surged 246.33% — and 2025, when it plunged 166.39%.
- Ocugen's Depreciation & Amortization (CF) stood at $173000.0 in 2022, then increased by 3.47% to $179000.0 in 2023, then surged by 234.08% to $598000.0 in 2024, then sank by 166.39% to -$397000.0 in 2025, then surged by 248.61% to $590000.0 in 2026.
- Business Quant data shows OCGN's Depreciation & Amortization (CF) at $590000.0 in Q1 2026, -$397000.0 in Q4 2025, and $950000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Ocugen | 63.79 Mn | 63.79 Mn | - | 590,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 590,000.00 |
| Mar 31, 2026 | 590,000.00 |
| Dec 31, 2025 | -397,000.00 |
| Dec 31, 2025 | -397,000.00 |
| Sep 30, 2025 | 950,000.00 |
| Sep 30, 2025 | 950,000.00 |
| Jun 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 595,000.00 |
| Mar 31, 2025 | 595,000.00 |
| Dec 31, 2024 | 598,000.00 |
| Dec 31, 2024 | 598,000.00 |
| Sep 30, 2024 | 613,000.00 |
| Sep 30, 2024 | 613,000.00 |
| Jun 30, 2024 | 578,000.00 |
| Jun 30, 2024 | 578,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |
| Dec 31, 2023 | 179,000.00 |